NASDAQ: AVBP

⬣ Investigation

Healthcare

ArriVent BioPharma, Inc.

Securities Investigation

Stock dropped 50%

Investors who purchased or acquired AVBP securities are encouraged to come forward.

Investigation in Progress — No Complaint Filed Yet

BG&G is actively investigating potential securities fraud claims against ArriVent BioPharma, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.

Why Is ArriVent BioPharma, Inc. (AVBP) Under Investigation?

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of shareholders of ArriVent BioPharma, Inc. (NASDAQ: AVBP).

On October 6, 2026, ArriVent BioPharma, Inc. announced that its global Phase 3 FURVENT trial evaluating firmonertinib in previously untreated patients with EGFR exon 20 insertion-mutated non-small-cell lung cancer failed to meet its primary endpoint of progression-free survival. Previously, the Company had stated in a November 10, 2025 filing that no interim analysis had been conducted or was planned, and subsequently filed a May 11, 2026 prospectus supporting an at-the-market offering of up to $250 million while describing its ongoing Phase 3 trial. The investigation concerns whether ArriVent adequately disclosed information regarding the trial’s progress and the timing of any negative efficacy data. Following the October 6 announcement, ArriVent’s stock price declined approximately 50%–63% during the trading session, reaching a 52-week low of approximately $12.09.

What Potential Securities Violations Is BG&G Investigating?

  • Whether ArriVent BioPharma, Inc. and certain of its officers made false or misleading statements regarding the Company's financial condition and business prospects.
  • Whether ArriVent BioPharma, Inc. failed to disclose material adverse information that would have been significant to a reasonable investor.
  • Whether the Company's earnings guidance was supported by a reasonable factual basis at the time it was made.

What Should ArriVent BioPharma, Inc. (AVBP) Investors Do?

If you purchased or acquired AVBP securities and suffered a loss, you may have a claim.
Contact BG&G to share relevant facts or information about your purchase.
There is no cost or obligation — our firm works exclusively on a contingency fee basis.
You do not need to have sold your shares to contact us.

How Is ArriVent BioPharma, Inc. (NASDAQ: AVBP) Stock Trading Today?

Interactive chart showing the weekly share price history of NASDAQ:AVBP (NASDAQ:AVBP).

How Does BG&G Help Investors in Securities Fraud Investigations?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

We handle cases on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”
— Peretz Bronstein, Founding Partner

Other Active Cases

ASTS Class Action

AST SpaceMobile, Inc.

Lead Plaintiff Deadline

November 13, 2026

View Case →
BIDU Class Action

Baidu, Inc.

Lead Plaintiff Deadline

November 13, 2026

View Case →
APP Class Action

AppLovin Corporation

Lead Plaintiff Deadline

November 16, 2026

View Case →
All Cases

View All Upcoming Deadlines

View Cases →

Investor Guides

Practice AreaHow Securities Class Actions WorkHow an investigation becomes a case, and what investors can do in the meantime.Learn More →
Investor Guide

The Difference Between a Securities Investigation and a Filed Lawsuit

Investor Guide

How Do I Know If I Lost Money in a Securities Fraud Case?

Investor Guide

What Is Securities Fraud and How Does It Happen?